ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M [Yahoo! Finance]
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: Yahoo! Finance
Esperion Therapeutics ESPR announced that it has entered into a definitive agreement to acquire Nevada-based, privately held, commercial-stage biopharmaceutical company, Corstasis Therapeutics, for up to $75 million in cash. The impending acquisition will add Corstasis' lead product, Enbumyst (bumetanide nasal spray), to Esperion's commercial portfolio, which is expected to strengthen and expand the company's cardiovascular franchise. Enbumyst is the first and only nasal spray diuretic approved by the FDA for the treatment of edema associated with congestive heart failure (CHF) and hepatic and renal disease in adults. The transaction is expected to be closed in the second quarter of 2026, subject to customary closing conditions. Shares of Esperion were down 11% yesterday following the announcement of the news. Year to date, shares of Esperion have plunged 21.4% against the industry's increase of 2%. Zacks Investment Research Image Source: Zacks Investment Research ESP
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- Daiichi and GAIA join forces to commercialise digital cardiovascular therapy [Yahoo! Finance]Yahoo! Finance
- GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe. [Yahoo! Finance]Yahoo! Finance
- GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.Business Wire
- Esperion to acquire Corstasis for cardiovascular franchise expansion [Yahoo! Finance]Yahoo! Finance
- Antibody-drug Conjugates (ADCs) in Oncology Market Competitive Landscape Report 2026: Comprehensive Insights About 200+ Companies and 220+ Drugs by Product Type, Stage, and Route of Administration [Yahoo! Finance]Yahoo! Finance